Pharmacyclics/AbbVie Deal History & Licensing Activity
Pharmacyclics/AbbVie is a life sciences. Over the past three years, Pharmacyclics/AbbVie has been involved in 32 licensing and acquisition transactions, with a primary focus on Small Molecules (11 deals). The company currently has 2 active clinical trials, primarily in Oncology.
Deals (12mo)
9
Active Trials
2
Top Modality
Small Molecules
Focus Area
Oncology
Pharmacyclics/AbbVie Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Pharmacyclics/AbbVie in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Imbruvica | Janssen | Small Molecules | Approved | co development | Jul 20, 2026 |
| ABBV-RGX-314 | AbbVie | Gene Therapy | Unknown | co development | Jun 15, 2026 |
| Undisclosed | AbbVie | Small Molecules | Unknown | collaboration | Apr 20, 2026 |
| Alveltamig | AbbVie | Bispecific Antibodies | Unknown | license | Apr 1, 2026 |
| Undisclosed | AbbVie | Unknown | Unknown | acquisition | Mar 6, 2026 |
| RC148 / ABBV-1480 | AbbVie | Bispecific Antibodies | Phase 1 | license | Mar 1, 2026 |
| RC148 (ABBV-1480) | AbbVie | Bispecific Antibodies | Phase 1 | license | Jan 12, 2026 |
| ZG006 (Alveltamig) | AbbVie | Antibodies | Unknown | license | Jan 4, 2026 |
| DLL3 trispecific antibody | AbbVie | Antibodies | Unknown | option | Dec 30, 2025 |
| ZG006 (Alveltamig) | AbbVie | Bispecific Antibodies | Unknown | option | Dec 30, 2025 |
Pharmacyclics/AbbVie Pipeline Focus
Therapeutic areas and modalities where Pharmacyclics/AbbVie is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Pharmacyclics/AbbVie Clinical Pipeline
Pharmacyclics/AbbVie has 2 active clinical trials across 2 development phases.
1
Phase 1
1
Phase 2
See How Your Asset Matches Pharmacyclics/AbbVie's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Pharmacyclics/AbbVie Licensing & Deal Activity
Pharmacyclics/AbbVie is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 32 deals over the past three years, Pharmacyclics/AbbVie ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Pharmacyclics/AbbVie include Oncology (20 deals and trials), Neurology (9 deals and trials), Immunology (5 deals and trials), and Codev Deals (2 deals and trials). In terms of modality, Pharmacyclics/AbbVie has shown particular interest in small molecules, bispecific antibodies, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Pharmacyclics/AbbVie and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Pharmacyclics/AbbVie's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.